Clinical experience with N-acetylcarnosine use in patients with age-related cataract

Abstract. Background. Cataract remains one of the most common diseases in the world leading to blindness. Pathological conditions associated with lens aging have long been known, including presbyopia and age-related cataract. That is why the World Health Organization supports the feasibility of further large-scale studies on the effectiveness of drugs for the prevention of cataract, especially
with the use of antioxidants (2018). The aim of the study was to evaluate the effect of N-acetylcarnosine contained in Clarastill on
the condition of the lens with long-term use (6 months) in patients with cataract. Materials and methods. The study lasted 6 months in
two groups. The first (control) group included 10 patients (18 eyes) aged 65.3 ± 3.0 years, the second group — 20 individuals (37 eyes)
aged 63.4 ± 5.0 years with a diagnosis of senile cataract. The study was conducted in accordance with the Declaration of Helsinki
1964. Patients in the first group did not receive any drops and were only monitored for the entire period. Patients in the second group
received Clarastill twice daily (local instillations into the conjunctival sac) for 6 months. Results. It was recorded that in the group of
patients who used N-acetylcarnosine, there was an improvement in visual acuity, results of achromatic visocontrastometry, Norn and
Schirmer tests, as well as the condition of the lens according to the Lens Opacities Classification System III. Conclusions. Clarastill
as a pharmaceutical product containing N-acetylcarnosine delays cataract progression and, in some cases, significantly restores lens
transparency in the initial (early) stages of cataract formation and can potentially significantly delay surgery.
Keywords: age-related cataract; achromatic visocontrastometry; lens; Lens Opacities Classification System III; antioxidants

 

Visuspharm